(Q57480564)

https://api.crossref.org/works/10.1517%2F14712590902926071

OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

A critical appraisal of clinical practice guidelines for the treatment of lower-limb osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Coxibs and NSAIDs--is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Update on guidelines for the treatment of chronic musculoskeletal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Selective cyclooxygenase 2 inhibitors and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Understanding the NSAID related risk of vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Building a better aspirin: gaseous solutions to a century-old problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Nitric oxide in inflammation and pain associated with osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Role of nitric oxide in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

The chemical biology of nitric oxide--an outsider's reflections about its role in osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Osteoarthritis and nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Nitric oxide and cardiovascular and renal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Nitric oxide: an endogenous modulator of leukocyte adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071

Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590902926071